Method of administration and treatment
Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.
1. A method of treating a breast cancer, comprising administering a transdermal formulation containing a buffering agent, wherein the buffering agent is sodium bicarbonate to a patient suffering from a breast cancer.
2. The method of claim 1 , wherein the transdermal formulation is administered to a patient topically.
3. The method of claim 1 , wherein, the transdermal formulation is effective in reducing the metastatic rate of a patient suffering from the breast cancer.
4. The method of claim 3 , wherein the reduction in the metastatic rate results in necrosis of the tumor.
5. The method of claim 3 , wherein administering the transdermal formulation to a patient suffering from the breast cancer reduces the formation of spontaneous metastases in the patient suffering from the breast cancer.
6. The method of claim 1 , wherein the method of administering the transdermal formulation reduces the metastatic rate in one or more of intestinal tissue, the mesentery, a lymph node or a lung of a patient suffering from the breast cancer.
7. The method of claim 6 , wherein the method of administering the transdermal formulation reduces the metastatic rate in the intestinal tissue by as much as 36% for a patient that is suffering from the breast cancer as compared to a patient who is not treated with the transdermal formulation.
8. The method of claim 6 , wherein the method of administering the transdermal formulation reduces the metastatic rate in the mesentery by as much as 14% for a patient that is suffering from the breast cancer as compared to a patient who is not treated with the transdermal formulation.
9. The method of claim 6 , wherein the method of administering the transdermal formulation reduces the metastatic rate in a lymph node by as much as 37% for a patient that is suffering from the breast cancer as compared to a patient who is not treated with the transdermal formulation.
10. The method of claim 6 , wherein the method of administering the transdermal formulation reduces the metastatic rate in the lung by as much as 71% for a patient that is suffering from the breast cancer as compared to a patient who is not treated with the transdermal formulation.
11. The method of claim 1 , wherein the method of administering the transdermal formulation to a patient suffering from the breast cancer increases the survival time of the patient as compared to a patient who is not treated with the transdermal formulation.
12. The method of claim 1 , wherein the administration of the transdermal formulation to a patient suffering from a breast cancer increases the mean tumor pH of a tumor associated with the breast cancer.
13. The method of claim 1 , wherein administration of the transdermal formulation results in the necrosis of a tumor associated with the breast cancer in a patient suffering from the breast cancer.
14. The method of claim 1 , wherein the sodium bicarbonate is at a concentration from about 1% to 35% w/w of the transdermal formulation.
15. The method of claim 1 , wherein the transdermal formulation comprises the buffering agent in an amount between about 10%-45% w/w; a penetrant portion in an amount between about 5%-55% w/w;
a detergent portion in an amount between about 1% to 15% w/w; and water in an amount between about 15% to 65% w/w.
16. The method of claim 1 , wherein the buffering agent constitutes between 10%-56% w/w of the transdermal formulation.
17. The method of claim 1 , wherein the buffering agent penetrates the skin of the patient.
18. The method of claim 1 , wherein the patient suffering from the breast cancer is a female.
19. The method of claim 1 , wherein the patient suffering from the breast cancer is a male.
20. The method of claim 1 , wherein the breast cancer is a metastatic breast cancer.